iconoclast - I'm a little surprised with your post. In my replies to CCD, Buckeyes and KK2 I specifically say, assuming we reach nirvana and hit a triple play, all referring to trial success. KK2 specifically referred to the sale of RVX, lock stock and barrel. The share price action leading up to the top line results announcement should only be considered if shareholders want to take risk off the table prior to the announcement. The trial results are double blinded so any share price action is shear speculation, some of which is designed to take shares out of the hands of those that are not committed but need to be.

Second, Zenith does not have to have any influence whatsoever on the sales of RVX. The purchaser of RVX negotiates knowing that there is a royalty outstanding. We have flogged this point to death over the last couple of years on this board. If the buyer wants to purchase Zenith then that is a totally separate transaction. If my memory serves correct I think it was fouremm that posted the list of drugs on the market that have royalties outstanding to third parties. It looked to be about half of the drugs on the market. The royalty is not a new concept in this field.

Third, the market has already told us what it values an Alzheimer's/dementia product at in the pricing of Biogen last July. It's between $16 and $19 billion for that indication alone, if we show success. After having said, if we hit the triple play, which infers success with diabetic CVD in a +30% RRR, CKD which infers an increase in eGFR and an increase in cognitive function referring to an increased MOCA score I respectfully disagree with a value of $5 to $6 billion. That is less than 1/3 of what the market valued BIIB's Alzheimer's program alone at last summer. As far as I know there is not a single drug available today to increase cognitive function, and that market in the US alone is growing at over 20% per year. The CVD potential alone is in excess of that 5 to 6 billion and the potential for a drug with a good safety profile for CKD is in excess of both the CVD and dementia market combined.

As I said to KOO, we will see what the analysts and potential buyers say after the results come out.

All in my opinion, do your own due diligence.

tada